October 27th, 2025
Presentation of Domestic Phase II Clinical Trial Results for Angiosarcoma at ESMO 2025
We are pleased to announce that the detailed results of the domestic Phase II c……
October 1st, 2025
Notice Regarding the Publication of Results of a Specified Clinical Study on Boron Neutron Capture Therapy (BNCT) for Recurrent Breast Cancer Following Radiotherapy
We are pleased to announce that the final report has been published for the inv……
July 30th, 2025
Paper published: Poly(vinyl alcohol) Enhancing Therapeutic Effects of 4-L-Boronophenylalanine on Thoracic Tumors in Neutron Capture Therapy
The paper published in the International Journal of Pharmaceutics describes the……
July 28th, 2025
Achievement of Primary Endpoints in Phase II Clinical Trial Targeting Angiosarcoma in Japan —Detailed Trial Results to Be Presented at ESMO Congress 2025—
We are pleased to announce that the Phase II clinical trial for angiosarc……
June 4th, 2025
We participated in the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
We, Stella Pharma, participated in the 2025 Annual Meeting of the American Soci……
May 23rd, 2025
Statistically Significant Difference in Results for Primary Endpoint of Clinical Trial for Recurrent High-Grade Meningioma – Presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Stella Pharma is pleased to announce the results of the Phase II investigator-i……
April 15th, 2025
Phase I/II Clinical Trial in Japan for Thoracic Malignant Solid Tumors has started
Stella Pharma announces that it has started the first patient trial for the do……
April 9th, 2025
Presentation on the Clinical Trial for Recurrent High-Grade Meningioma at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
At the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO),……
We are proud to announce that we will exhibit at the Osaka Healthcare Pavilion ……
We are pleased to announce that we have successfully completed the first shipme……
December 25th, 2024
Stella Pharma Concludes MOU on Boron Neutron Capture Therapy System with Fujita Health University, Atransen Pharma, SHI, and Fujita
Stella Pharma Corporation has concluded a Memorandum of Understanding (MOU) to ……
December 10th, 2024
Observation Period Completed for Primary Endpoint – Phase II Clinical Trial in Patients with Angiosarcoma
We are pleased to announce the completion of the 90-day observation period for ……
